Effect of oral contraceptives on vitamin K—dependent clotting activtiy

Vitamin K‐dependent clotting factor activity was studied in young, healthy women being treated with various oral contraceptive drugs. In one series of studies, the anticoagulant response to a dose of bishydroxycoumarin was diminished following treatment with an estrogen‐progestin mixture; the metabolism of the anticoagulant was unaffected. Thus the amount of coumarin‐type drug required to produce a desired anticoagulant effect in women taking oral contraceptives may be increased. In other studies, a marked shortening of the prothrombin time was observed in the plasmas of a majority of the women treated with oral contraceptives for two months or longer. This effect was demonstrated only after storage of the patients' plasmas in plastic tubes for 16 hours or more at 4 to 6°C. Following storage, the vitamin K‐dependent clotting activity of pooled treated plasma was 4.8 times that of pooled control plasma. This effect persisted for at least seven days following discontinuance of therapy but disappeared after one month. Assays of specific factors demonstrated an increase in the activity of factor X in stored plasmas from treated subjects. Oral contraceptives may affect the plasma of treated subjects so that there is in vitro activation of one or more of the inactive precursors of the vitamin K‐dependent clotting factors.

[1]  H. M. Solomon,et al.  II. The effect of D‐thyroxine, clofibrate, and norethandrolone , 1967 .

[2]  V. Wynn,et al.  Some effects of oral contraceptives on serum-lipid and lipoprotein levels. , 1966, Lancet.

[3]  L. Poller,et al.  Clotting Factors during Oral Contraception: Further Report , 1966, British medical journal.

[4]  S. P. Miller,et al.  PROGESTIN-ESTROGEN (SC 11,800) THERAPY AND THE HEMOSTATIC MECHANISM--A CONTROLLED STUDY. , 1965, Metabolism: clinical and experimental.

[5]  C. Hougie,et al.  EFFECT OF A PROGESTIN-ESTROGEN ORAL CONTRACEPTIVE ON BLOOD CLOTTING FACTORS. , 1965, Metabolism: clinical and experimental.

[6]  T. O. Soine NATURALLY OCCURRING COUMARINS AND RELATED PHYSIOLOGICAL ACTIVITIES. , 1964, Journal of pharmaceutical sciences.

[7]  C. Hussey,et al.  PROTHROMBIN: ANALYTICAL AND CLINICAL ASPECTS COMPARISON OF THE ONE‐ AND TWO‐STAGE METHODS , 1963, American Journal of the Medical Sciences.

[8]  B. Johnson,et al.  Relationship of Estrogen and Vitamin K.∗ , 1963, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[9]  P. Owren,et al.  Oral Contraception and Blood Coagulability , 1963, British medical journal.

[10]  S. J. Mellette Interrelationships between vitamin K and estrogenic hormones. , 1961, American Journal of Clinical Nutrition.

[11]  E. Bickoff,et al.  Estrogenic activity of coumestrol and related compounds. , 1960, Archives of biochemistry and biophysics.

[12]  J. Poole The effect of certain fatty acids on the coagulation of plasma in vitro. , 1955, British journal of experimental pathology.

[13]  W. Walther,et al.  The control of anticoagulant therapy. , 1951, Lancet.

[14]  M. Stefanini,et al.  The state of component A (prothrombin) in human blood; evidence that it is partly free and partly in an inactive or precursor form. , 1949, The Journal of laboratory and clinical medicine.

[15]  J. Cooper,et al.  Estimation of Dicumarol, 3, 31-Methylenebis (4-Hydroxycoumarin) in Biological Fluids.* , 1949, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.